U.S. health regulators are expected to authorize a booster shot of Pfizer/BioNTech’s COVID-19 vaccine for children aged 5 to 11 as soon as May 17, the New York Times reported on May 16, citing people familiar with the matter.
Although 2020 was a tough year for the biopharma industry — and most other industries as well — it appeared to rebound significantly in mid-2021. However, biotech stocks are generally getting hammered during 2022, although to be fair, the entire stock market is down.
Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
The Chinese government halted the recommendation of an herbal supplement used as a traditional Chinese treatment for mild cases of COVID-19.
An AstraZeneca Plc executive said the British drugmaker would consider not submitting the company’s COVID-19 vaccine for approval in the United States if the regulatory process takes too long, the Financial Times reported on March 17.
U.S. Bankruptcy Court Judge Michael Kaplan ruled that Johnson & Johnson be allowed to continue with the company’s controversial spinoff strategy to settle with people who filed lawsuits claiming that J&J’s talc-based baby powder causes cancer.
Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic. And these companies that have seen declining investor interest are now struggling to raise finances, according to BioSpace
The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.
With companies like GlaxoSmithKline and bluebird bio moving closer to splitting their businesses into multiple entities, Novartis is reviewing the Swiss drugmaker’s Sandoz division to determine the best moves going forward to maximize value for shareholders.
The world is at risk of losing hard-won gains in fighting Covid-19 as the highly transmissible Delta variant spreads, but WHO-approved vaccines remain effective, the World Health Organization said on July 30.